Fluorine Atoms on C6H5-Corrole Affect the Interaction with Mpro and PLpro Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches

The chymotrypsin-like cysteine protease (3CLpro, also known as main protease—Mpro) and papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been used as the main targets for screening potential synthetic inhibitors for posterior in vitro evaluation of the most promising compounds. In this sense, the present work reports for the first time the evaluation of the interaction between Mpro/PLpro with a series of 17 porphyrin analogues-corrole (C1), meso-aryl-corrole (C2), and 15 fluorinated-meso-aryl-corrole derivatives (C3–C17) via molecular docking calculations. The impact of fluorine atoms on meso-aryl-corrole structure was also evaluated in terms of binding affinity and physical-chemical properties by two-dimensional quantitative structure–activity relationship (2D-QSAR). The presence of phenyl moieties increased the binding capacity of corrole for both proteases and depending on the position of fluorine atoms might impact positively or negatively the binding capacity. For Mpro the para-fluorine atoms might decrease drastically the binding capacity, while for PLpro there was a certain increase in the binding affinity of fluorinated-corroles with the increase of fluorine atoms into meso-aryl-corrole structure mainly from tri-fluorinated insertions. The 2D-QSAR models indicated two separated regions of higher and lower affinity for Mpro:C1–C17 based on dual electronic parameters (σI and σR), as well as one model was obtained with a correlation between the docking score value of Mpro:C2–C17 and the corresponding 13C nuclear magnetic resonance (NMR) chemical shifts of the sp2 carbon atoms (δC-1 and δC-2) of C2–C17. Overall, the fluorinated-meso-aryl-corrole derivatives showed favorable in silico parameters as potential synthetic compounds for future in vitro assays on the inhibition of SARS-CoV-2 replication.

[1]  Carolina Q. Sacramento,et al.  Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones , 2022, Viruses.

[2]  H. Castro-Faria-Neto,et al.  Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way , 2022, Journal of molecular cell biology.

[3]  S. Olsen,et al.  Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development , 2022, Frontiers in Chemistry.

[4]  Carolina Q. Sacramento,et al.  Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo , 2021, bioRxiv.

[5]  B. Iglesias,et al.  Unveiling the photophysical, biomolecule binding and photo-oxidative capacity of novel Ru(II)-polypyridyl corroles: A multipronged approach , 2021 .

[6]  Sangdun Choi,et al.  Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations , 2021, International journal of molecular sciences.

[7]  Carolina Q. Sacramento,et al.  SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites , 2021, International journal of molecular sciences.

[8]  M. Lebedev,et al.  Possible therapeutic targets and promising drugs based on unsymmetrical hetaryl-substituted porphyrins to combat SARS-CoV-2 , 2021, Journal of Pharmaceutical Analysis.

[9]  O. Koifman,et al.  Modeling the binding of protoporphyrin IX, verteporfin, and chlorin e6 to SARS-CoV-2 proteins , 2021, Chemistry of Heterocyclic Compounds.

[10]  Yann-Mickael Dalmat Sars-CoV-2 : histoire de mutants , 2021, Option/Bio.

[11]  S. Irfan,et al.  Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19 , 2021, Saudi Journal of Biological Sciences.

[12]  M. Lonardoni,et al.  A systematic review of photodynamic therapy as an antiviral treatment: Potential guidance for dealing with SARS-CoV-2 , 2021, Photodiagnosis and Photodynamic Therapy.

[13]  A. Kasry,et al.  The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant , 2021, Medicine in Drug Discovery.

[14]  T. Tencomnao,et al.  Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach , 2021, Journal of Traditional and Complementary Medicine.

[15]  R. Menna-Barreto,et al.  Novel N,N-di-alkylnaphthoimidazolium derivative of β-lapachone impaired Trypanosoma cruzi mitochondrial electron transport system. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  M. Baig,et al.  Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19 , 2020, Current Research in Structural Biology.

[17]  L. Perera,et al.  Potential SARS-CoV-2 main protease inhibitors , 2020, Drug Discovery Today.

[18]  D. Qu,et al.  Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2 , 2020, Science Bulletin.

[19]  Jaeyong Lee,et al.  Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site , 2020, Nature Communications.

[20]  Tao Wang,et al.  Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection , 2020, Biomedicine & Pharmacotherapy.

[21]  B. Iglesias,et al.  Fluorescent pyrene moiety in fluorinated C6F5-corroles increases the interaction with HSA and CT-DNA , 2020 .

[22]  S. Gayen,et al.  Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors , 2020, Bioorganic & Medicinal Chemistry.

[23]  I. Tuñón,et al.  Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods , 2020, ACS catalysis.

[24]  Robert C. Harris,et al.  Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors , 2020, The Journal of chemical physics.

[25]  Kanikar Muangchoo,et al.  A Computational Study to Identify Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) from Eucalyptus Active Compounds , 2020, Comput..

[26]  Meitian Wang,et al.  Crystal structure of SARS-CoV-2 papain-like protease , 2020, Acta Pharmaceutica Sinica B.

[27]  Cooper A. Taylor,et al.  Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors , 2020, Nature Communications.

[28]  Carolina Q. Sacramento,et al.  Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production , 2020, Antimicrobial Agents and Chemotherapy.

[29]  W. D. dos Santos,et al.  Natural history of COVID-19 and current knowledge on treatment therapeutic options , 2020, Biomedicine & Pharmacotherapy.

[30]  J. J. Rodríguez,et al.  Synthesis and photophysics of benzazole based triazoles with amino acid-derived pendant units. Multiparametric optical sensors for BSA and CT-DNA in solution , 2020 .

[31]  F. Iacovelli,et al.  Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors , 2020, Virus Research.

[32]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[33]  A. Joachimiak,et al.  Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography , 2020, Nature Communications.

[34]  J. Tuszynski,et al.  Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design , 2020, International journal of molecular sciences.

[35]  Mubarak A. Alamri,et al.  Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.

[36]  N. Kipshidze,et al.  Photodynamic therapy for COVID-19 , 2020, Nature Photonics.

[37]  O. Santos-Filho Identification of Potential Inhibitors of Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Main Protease from Non-Natural and Natural Sources: A Molecular Docking Study , 2020 .

[38]  Hui-Yao Huang,et al.  The photodynamic activity and toxicity evaluation of 5,10,15-tris(ethoxylcarbonyl)corrole phosphorus(V) in vivo and in vitro. , 2019, European journal of medicinal chemistry.

[39]  B. Röder,et al.  Singlet oxygen luminescence kinetics under PDI relevant conditions of pathogenic dermatophytes and molds. , 2018, Journal of photochemistry and photobiology. B, Biology.

[40]  Proton-Coupled Conformational Allostery Modulates the Inhibitor Selectivity for β-Secretase. , 2017, The journal of physical chemistry letters.

[41]  R. P. Pereira,et al.  Investigation of interaction between human plasmatic albumin and potential fluorinated anti-trypanosomal drugs , 2017 .

[42]  C. M. Sant’Anna,et al.  Biological interactions of fluorinated chalcones: Stimulation of tyrosinase activity and binding to bovine serum albumin , 2017 .

[43]  H. Gray,et al.  Fighting Cancer with Corroles. , 2017, Chemical reviews.

[44]  A. Mesecar,et al.  The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds , 2014, Antiviral Research.

[45]  A. Bortoluzzi,et al.  Synthesis, antileishmanial activity and structure-activity relationship of 1-N-X-phenyl-3-N'-Y-phenyl-benzamidines. , 2013, European journal of medicinal chemistry.

[46]  T. Goslinski,et al.  Fluorinated porphyrinoids and their biomedical applications , 2011 .

[47]  Andrew D Westwell,et al.  The role of fluorine in medicinal chemistry , 2007, Journal of enzyme inhibition and medicinal chemistry.

[48]  Zhongbin Chen,et al.  The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity , 2005, Journal of Virology.

[49]  D. Gryko,et al.  Photophysical characterization of free-base corroles, promising chromophores for light energy conversion and singlet oxygen generation , 2005 .

[50]  D. Modarelli,et al.  Photophysical properties of a series of free-base corroles. , 2005, The journal of physical chemistry. A.

[51]  L. Eriksson,et al.  Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. , 2003, Environmental Health Perspectives.

[52]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[53]  Eliana Zandonade,et al.  Proposição, validação e análise dos modelos que correlacionam estrutura química e atividade biológica , 2001 .

[54]  U Norinder,et al.  Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[55]  Anderson Coser Gaudio,et al.  BuildQSAR: A New Computer Program for QSAR Analysis , 2000 .

[56]  N. Galili,et al.  Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. , 2000, Cancer research.

[57]  Gary O. Spessard,et al.  ACD Labs/LogP dB 3.5 and ChemSketch 3.5 , 1998, J. Chem. Inf. Comput. Sci..

[58]  W. A. WATERS,et al.  Physical Organic Chemistry: , 1941, Nature.